Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project

Fabio Efficace, Adriano Venditti, Thomas Baldi, Joanna Canham, Giovanni Martinelli, Alfonso Piciocchi, Mike Dennis, Steve Knapper, Nigel H. Russell, Sean Johnson, Maria Teresa Voso, Marco Vignetti, Ian Thomas

Blood (2024) 144 (Supplement 1): 407.

https://doi.org/10.1182/blood-2024-204588

Published: 2024

Journal Articles

Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19

Blood (2024) 144 (Supplement 1): 845.

https://doi.org/10.1182/blood-2024-201097

Published: 2024

Journal Articles

Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial

Ian Thomas, Joanna Canham, Sean Johnson, Nuria Marquez, Sophie King, Jane Leahy, Mike Dennis, Nigel H. Russell, Abin Thomas, Steven Knapper

Blood (2024) 144 (Supplement 1): 3805.

https://doi.org/10.1182/blood-2024-198870

Published: 2024

Journal Articles

Optimising Therapy in FLT3 -Mutated Acute Myeloid Leukaemia

Joanna Canham, Angela Casbard, Sylvie D Freeman, Nicola Potter, Abin Thomas, Amanda Gilkes, Sean Johnson, Lucy Marsh, Jane Leahy, Hayley Timmins, Richard Dillon, Steve Knapper

Blood (2024) 144 (Supplement 1): 4191.1.

https://doi.org/10.1182/blood-2024-204975

Published: 2024

Journal Articles

Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 ‘Midotarg Pilot‘

Joanna Canham, Ian Thomas, Nigel H. Russell, Jane Leahy, Abin Thomas, Steve Knapper, Lucy Marsh, Huda Mohamed, Sean Johnson

Blood (2024) 144 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2024-205133

Published: 2024

Journal Articles

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Blood (2024) 144 (7): 714–728.

https://doi.org/10.1182/blood.2024024310

Published: 2024

Includes: Supplemental data

Journal Articles

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Blood (2024) 143 (19): 1931–1936.

https://doi.org/10.1182/blood.2023023096

Published: 2024

Includes: Supplemental data

Journal Articles

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Sylvie D Freeman, Amanda Gilkes, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panos Kottaridis, Claire Arnold, Ulrik Malthe Overgaard, Mike Dennis, Charlotte Wilhelm-Benartzi, Richard Dillon, Nigel Russell

Blood (2023) 142 (Supplement 1): 425.

https://doi.org/10.1182/blood-2023-179033

Published: 2023

Journal Articles

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Blood (2023) 142 (Supplement 1): 2939.

https://doi.org/10.1182/blood-2023-179036

Published: 2023

Journal Articles

Pretransplant FLT3 -ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Blood (2022) 140 (22): 2407–2411.

https://doi.org/10.1182/blood.2022016567

Published: 2022

Includes: Supplemental data

Journal Articles

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1 m Patients Achieving MRD-Negative CR after Intensive Induction

Blood (2022) 140 (Supplement 1): 6293–6294.

https://doi.org/10.1182/blood-2022-159212

Published: 2022

Journal Articles

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

Luis A. Carvajal, Tressa Hood, Yana Bevan, Richard Dillon, Nicola Potter, Ian Thomas, Sean Johnson, Jad Othman, Amanda Gilkes, Nigel H. Russell, Adam Sikorski, Pete Ellis, Giovanni Marsico, Greg Jones, Crystal MacKenzie, Zung To, Jorge DiMartino, Pavan Kumar

Blood (2022) 140 (Supplement 1): 3377–3378.

https://doi.org/10.1182/blood-2022-159154

Published: 2022

Journal Articles

High Sensitivity Detection of FLT3 -ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia

Sun Loo, Richard Dillon, Natasha S Anstee, Ing S Tiong, Adam Ivey, Nicola Potter, Jad Othman, Manohursingh Runglall, Jelena Jovanovic, Amanda Gilkes, Ian Thomas, Sean Johnson, Nigel H. Russell, Andrew H. Wei

Blood (2021) 138 (Supplement 1): 2364.

https://doi.org/10.1182/blood-2021-149301

Published: 2021

NARROW

Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project

Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19

Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial

Optimising Therapy in FLT3 -Mutated Acute Myeloid Leukaemia

Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 ‘Midotarg Pilot‘

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Pretransplant FLT3 -ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1 m Patients Achieving MRD-Negative CR after Intensive Induction

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

High Sensitivity Detection of FLT3 -ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only